Kazia Therapeutics grants Oasmia exclusive rights for first-in-class ovarian cancer drug candidate Cantrixil
Euro Manganese target price more than doubled by Canaccord Genuity
Red River Resources pours first gold at Hillgrove Mine and ramps up production
Andromeda Metals passes key milestone by submitting mining lease application for Great White Kaolin Project
Coffee with Samso: Finding nickel sulphide in Tanzania - Adavale Resources
Oasmia Pharmaceutical AB will assume worldwide exclusive rights to develop and commercialise Cantrixil for all indications, with an initial focus on ovarian cancer.
Canaccord has lifted EMN’s price target to A$1.30 (from A$O.55) and has maintained a speculative buy recommendation.
The pour is a key step in the company’s strategy to build a multi-asset operating business focused on precious and base metals with the objective of delivering prosperity through lean and clever resource development.
Lodgement of the applications with the South Australian Government represents a milestone for the company which is focused on the commencement of operations in February 2022.
The electric vehicle revolution has thrown the world of battery metals, including nickel, into another rush for good assets.